微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 78.42% | -4.14% | 0.83% | 23/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 77.77% | -5.52% | -3.78% | 23/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 80.83% | -1.71% | -1.19% | 21/159 | 51.78% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 81.8% | 0.08% | -0.63% | 19/159 | 22.81% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 82.32% | -0.84% | -1.67% | 16/159 | 33.25% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 83.72% | -0.32% | 1.81% | 12/159 | 51.56% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 82.23% | 0.87% | 0.6% | 17/159 | 51.39% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 81.74% | 0.82% | -1.54% | 17/159 | 32.56% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 83.02% | 2.43% | -1.15% | 17/159 | 38.45% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 83.99% | 8.91% | 3.02% | 17/159 | 52.78% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 81.52% | 0.77% | 0.55% | 20/159 | 53.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 81.08% | -0.03% | 0.03% | 19/159 | 6.2% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 81.05% | -0.77% | 5.11% | 23/159 | 21.37% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 77.11% | -5.91% | -4.67% | 29/159 | 54.28% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 80.9% | -1.03% | -0.25% | 26/159 | 55.1% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 81.1% | -1.81% | -0.71% | 21/159 | 46.78% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 81.68% | 0.46% | -0.33% | 21/159 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 81.96% | 0.62% | 0.26% | 15/159 | 53.99% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 81.74% | -6.87% | -1.04% | 19/159 | -145.9% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 82.6% | -6.43% | 1.59% | 15/159 | 56.36% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 81.31% | -8.27% | -0.17% | 16/159 | 54.11% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 81.45% | -8.01% | -7.21% | 15/159 | 55.23% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 87.77% | -3.25% | -0.57% | 8/159 | -1222.98% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 88.28% | -2.98% | -0.4% | 4/159 | 55.21% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 88.64% | -3.28% | 0.11% | 5/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 88.54% | -4.02% | -2.4% | 4/159 | 51.05% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 90.72% | -3.95% | -0.3% | 5/159 | -208.09% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 90.99% | -3.95% | -0.72% | 4/159 | 53.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 91.65% | -3.56% | -0.66% | 4/159 | 53.39% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 92.25% | -3.09% | -2.33% | 4/159 | 53.9% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 94.46% | -0.54% | -0.29% | 3/159 | 52.32% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 94.73% | 0.03% | -0.31% | 2/159 | 49% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 95.03% | 0.56% | -0.17% | 2/159 | 47.74% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 95.19% | 0.86% | 0.23% | 2/159 | 46.55% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 94.97% | 0.42% | 0.29% | 3/159 | 48.19% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 94.7% | 0.32% | 0.22% | 2/159 | 45.76% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 94.49% | 0.35% | 0.12% | 2/159 | 45.89% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 94.38% | -0.11% | -0.2% | 1/159 | 43.5% | 微芯生物 | 97.46% | 行业排名> |
| 2015-12-31 | 94.57% | 0.19% | 0.18% | 3/159 | 45.97% | 贝达药业 | 97.01% | 行业排名> |
| 2015-09-30 | 94.4% | 0.08% | 0.25% | 1/159 | 44.69% | 贝达药业 | 97.02% | 行业排名> |
| 2015-06-30 | 94.16% | -0.06% | -0.34% | 1/159 | 45% | 舒泰神 | 94.38% | 行业排名> |
| 2015-03-31 | 94.49% | -0.48% | 0.1% | 1/159 | 43.46% | 贝达药业 | 96.95% | 行业排名> |